These trials will evaluate the safety and efficacy of Isolagen therapy in patients with moderate to severe acne scarring on both sides of the face. All patients in the study will receive active treatment on one side of the face and placebo on the other, serving as their own control subjects. The patients will receive three injections, two weeks apart, and be followed for a four month period after final injection.
Nicholas Teti, Jr. chairman and CEO of Isolagen, said: “Millions of people in the US suffer from acne which often scars, a condition that can be very distressing and difficult to treat as there are few options currently available. We are pleased to be initiating this important clinical development program which we believe will address this largely unmet medical need.”